pacritinib
cti biopharma
['vonjo']
 in this novel, risk-adjusted analysis, this project demonstrated that the safety profile of (vonjo) is comparable to (best available therapy), said study author of of the findings in myelofibrosis at #asco22 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.